fda sued over tirzepatide Compounders lose battle Eli Lilly weight loss drug and shortage list FDA's tirzepatide decision creates uncertainty

Risk increases with: Too few calories or skipped meals , leading to protein breakdown for energy Inadequate protein intake , especially near minimal dietary requirements rather than weight-lossappropriate targets Lack of resistance training , removing the signal to maintain muscle Micronutrient deficiencies , such as low vitamin D, which can impair muscle function Preventing undernutrition dramatically reduces the risk of clinically meaningful muscle loss. How Common Is Lean-Mass Loss with GLP-1/GIP Therapy

Our team provides accountability and guidance to help you overcome challenges that may have impacted past efforts

For obesity treatment (Wegovy), coverage is inconsistent: some employers cover it to reduce long-term cardiometabolic costs, while others exclude weight-loss drugs to avoid budget increases

Thats old school